Amphastar Pharmaceuticals (NASDAQ:AMPH) Reaches New 52-Week Low – Time to Sell?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) shares reached a new 52-week low during mid-day trading on Monday . The company traded as low as $32.08 and last traded at $31.96, with a volume of 18089 shares. The stock had previously closed at $32.37.

Analyst Ratings Changes

A number of equities analysts recently weighed in on AMPH shares. Piper Sandler cut Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $66.00 to $36.00 in a report on Tuesday, February 4th. StockNews.com cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Finally, Wells Fargo & Company assumed coverage on shares of Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They set an “equal weight” rating and a $55.00 price target for the company. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $50.33.

Amphastar Pharmaceuticals Price Performance

The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The firm’s fifty day moving average price is $38.14 and its 200-day moving average price is $43.71. The stock has a market cap of $1.55 billion, a P/E ratio of 10.73, a PEG ratio of 2.07 and a beta of 0.81.

Insider Buying and Selling at Amphastar Pharmaceuticals

In related news, EVP Rong Zhou sold 6,893 shares of the business’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $48.88, for a total transaction of $336,929.84. Following the transaction, the executive vice president now owns 118,388 shares in the company, valued at $5,786,805.44. The trade was a 5.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Richard K. Prins sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $43.77, for a total value of $437,700.00. Following the sale, the director now directly owns 30,471 shares in the company, valued at approximately $1,333,715.67. The trade was a 24.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 28,893 shares of company stock worth $1,329,570. 27.10% of the stock is currently owned by company insiders.

Institutional Trading of Amphastar Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Victory Capital Management Inc. increased its stake in shares of Amphastar Pharmaceuticals by 10.9% during the third quarter. Victory Capital Management Inc. now owns 218,531 shares of the company’s stock valued at $10,605,000 after purchasing an additional 21,530 shares in the last quarter. International Assets Investment Management LLC purchased a new position in Amphastar Pharmaceuticals during the third quarter valued at $11,070,000. Pacer Advisors Inc. boosted its holdings in Amphastar Pharmaceuticals by 51,977.4% in the fourth quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company’s stock worth $50,139,000 after acquiring an additional 1,347,775 shares in the last quarter. Wellington Management Group LLP purchased a new stake in shares of Amphastar Pharmaceuticals in the third quarter worth $957,000. Finally, XTX Topco Ltd bought a new position in shares of Amphastar Pharmaceuticals during the third quarter valued at $674,000. 65.09% of the stock is owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.